Pyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest Update

Pyxis Oncology, Inc. (NASDAQ:PYXS) was the target of a large growth in short interest during the month of July. As of July 15th, there was short interest totalling 3,520,000 shares, a growth of 52.4% from the June 30th total of 2,310,000 shares. Based on an average daily trading volume, of 578,900 shares, the days-to-cover ratio is presently 6.1 days. Approximately 7.4% of the shares of the company are sold short.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Pyxis Oncology in a research note on Thursday, May 16th. Jefferies Financial Group restated a “buy” rating and issued a $10.00 price target on shares of Pyxis Oncology in a research report on Tuesday, May 7th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $8.80.

Hedge Funds Weigh In On Pyxis Oncology

Several institutional investors have recently added to or reduced their stakes in PYXS. Fullcircle Wealth LLC bought a new position in shares of Pyxis Oncology in the second quarter worth about $40,000. SG Americas Securities LLC bought a new position in shares of Pyxis Oncology in the first quarter worth about $59,000. Cetera Advisors LLC bought a new position in shares of Pyxis Oncology in the first quarter worth about $100,000. Cable Car Capital LLC bought a new position in shares of Pyxis Oncology in the fourth quarter worth about $111,000. Finally, Susquehanna Fundamental Investments LLC bought a new position in shares of Pyxis Oncology in the first quarter worth about $351,000. 39.09% of the stock is owned by institutional investors.

Pyxis Oncology Price Performance

Shares of Pyxis Oncology stock traded up $0.03 during trading on Friday, hitting $3.88. 320,243 shares of the company’s stock traded hands, compared to its average volume of 930,428. Pyxis Oncology has a twelve month low of $1.35 and a twelve month high of $6.85. The company has a market cap of $228.49 million, a PE ratio of -2.85 and a beta of 1.28. The firm’s fifty day moving average price is $3.50 and its 200 day moving average price is $4.15.

Pyxis Oncology (NASDAQ:PYXS) last announced its quarterly earnings results on Saturday, May 11th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.19. The firm had revenue of $16.15 million for the quarter, compared to the consensus estimate of $4.25 million. As a group, equities research analysts anticipate that Pyxis Oncology will post -1.09 earnings per share for the current year.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.